Spots Global Cancer Trial Database for biological therapy
Every month we try and update this database with for biological therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer | NCT00003536 | Stage IV Breast... Recurrent Breas... | antineoplaston ... methotrexate alternative pro... biological ther... biologically ba... cancer preventi... chemotherapy complementary a... differentiation... | - | National Cancer Institute (NCI) | |
| Antineoplaston Therapy in Treating Patients With Colon Cancer | NCT00003486 | Stage IV Colon ... Recurrent Colon... Adenocarcinoma ... | antineoplaston ... antineoplaston ... alternative pro... biological ther... biologically ba... cancer preventi... complementary a... differentiation... | 18 Years - | National Cancer Institute (NCI) | |
| Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma | NCT00265928 | Lymphoma | bortezomib rituximab antibody therap... biological ther... enzyme inhibito... monoclonal anti... | 18 Years - | National Cancer Institute (NCI) | |
| Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission | NCT00101140 | Adult Acute Ery... Adult Acute Mon... Adult Acute Mye... | anti-thymocyte ... fludarabine pho... thiotepa biological ther... bone marrow abl... chemotherapy non-specific im... peripheral bloo... radiation thera... | 18 Years - 59 Years | Eastern Cooperative Oncology Group | |
| Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer | NCT00002482 | Unspecified Adu... | antibody therap... biological ther... muromonab-CD3 cyclophosphamid... | 18 Years - | National Cancer Institute (NCI) | |
| Fluorouracil, Semustine, and Vincristine Compared With BCG in Treating Patients With Dukes' B or Dukes' C Colon Cancer That Has Been Removed By Surgery | NCT00427570 | Colorectal Canc... | BCG vaccine biological ther... fluorouracil semustine vincristine sul... | - 79 Years | National Cancer Institute (NCI) | |
| Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma | NCT01404702 | Neuroblastoma | Zoledronic Acid Aldesleukin | 2 Years - 21 Years | University of Alabama at Birmingham | |
| Celecoxib in Preventing Skin Cancer | NCT00025051 | Non-melanomatou... | celecoxib anti-cytokine t... antiangiogenesi... biological ther... cancer preventi... chemoprevention... growth factor a... | 20 Years - 60 Years | National Cancer Institute (NCI) | |
| S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix | NCT00072540 | Stage 0 Cervica... High-grade Squa... | celecoxib anti-cytokine t... antiangiogenesi... biological ther... cancer preventi... chemoprevention... enzyme inhibito... growth factor a... | 18 Years - | SWOG Cancer Research Network | |
| Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma | NCT00112879 | Stage I Multipl... Stage II Multip... Stage III Multi... Refractory Plas... | arsenic trioxid... ascorbic acid dexamethasone thalidomide anti-cytokine t... antiangiogenesi... biological ther... chemotherapy drug resistance... growth factor a... non-specific im... | 18 Years - | National Cancer Institute (NCI) | |
| Fluorouracil, Semustine, and Vincristine Compared With BCG in Treating Patients With Dukes' B or Dukes' C Colon Cancer That Has Been Removed By Surgery | NCT00427570 | Colorectal Canc... | BCG vaccine biological ther... fluorouracil semustine vincristine sul... | - 79 Years | National Cancer Institute (NCI) | |
| Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors | NCT00227773 | Gastrointestina... Islet Cell Carc... | octreotide acet... vatalanib anti-cytokine t... antiangiogenesi... biological ther... endocrine thera... enzyme inhibito... growth factor a... hormone therapy protein tyrosin... somatostatin an... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma | NCT00003505 | Primary Central... | antineoplaston ... antineoplaston ... alternative pro... biological ther... biologically ba... cancer preventi... complementary a... differentiation... | 18 Years - | National Cancer Institute (NCI) | |
| Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer | NCT00705315 | Breast Cancer | Docetaxel Epirubicin Bevacizumab | 18 Years - 75 Years | Hellenic Oncology Research Group | |
| Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease | NCT00515892 | Leukemia Non-Hodgkin's L... NHL | Immunotoxin the... CAT-8015 Immuno... Biological ther... Antibody Therap... Monoclonal Anti... | 18 Years - | Cambridge Antibody Technology | |
| S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix | NCT00072540 | Stage 0 Cervica... High-grade Squa... | celecoxib anti-cytokine t... antiangiogenesi... biological ther... cancer preventi... chemoprevention... enzyme inhibito... growth factor a... | 18 Years - | SWOG Cancer Research Network | |
| Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer | NCT00003536 | Stage IV Breast... Recurrent Breas... | antineoplaston ... methotrexate alternative pro... biological ther... biologically ba... cancer preventi... chemotherapy complementary a... differentiation... | - | National Cancer Institute (NCI) | |
| Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease | NCT00457860 | Leukemia | Immunotoxin the... CAT-8015 immuno... Biological ther... | 18 Years - | Cambridge Antibody Technology | |
| Efficacy Study of an Anti-Tumor Necrosis Factor (TNF) Alpha Agent in Patients With Hand Osteoarthritis | NCT00597623 | Hand Osteoarthr... | Adalimumab (Hum... Placebo | 40 Years - 80 Years | Assistance Publique - Hôpitaux de Paris | |
| S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix | NCT00072540 | Stage 0 Cervica... High-grade Squa... | celecoxib anti-cytokine t... antiangiogenesi... biological ther... cancer preventi... chemoprevention... enzyme inhibito... growth factor a... | 18 Years - | SWOG Cancer Research Network | |
| Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer | NCT00003517 | Adenocarcinoma ... Stage III Prost... Stage IV Prosta... Recurrent Prost... | antineoplaston ... antineoplaston ... bicalutamide flutamide leuprolide acet... alternative pro... antiandrogen th... biological ther... biologically ba... cancer preventi... complementary a... differentiation... endocrine thera... hormone therapy | 18 Years - | National Cancer Institute (NCI) | |
| Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease | NCT00515892 | Leukemia Non-Hodgkin's L... NHL | Immunotoxin the... CAT-8015 Immuno... Biological ther... Antibody Therap... Monoclonal Anti... | 18 Years - | Cambridge Antibody Technology | |
| Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission | NCT00101140 | Adult Acute Ery... Adult Acute Mon... Adult Acute Mye... | anti-thymocyte ... fludarabine pho... thiotepa biological ther... bone marrow abl... chemotherapy non-specific im... peripheral bloo... radiation thera... | 18 Years - 59 Years | Eastern Cooperative Oncology Group | |
| Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer | NCT00400803 | Carcinoma, Non-... | Gemcitabine, Ca... | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors | NCT00227773 | Gastrointestina... Islet Cell Carc... | octreotide acet... vatalanib anti-cytokine t... antiangiogenesi... biological ther... endocrine thera... enzyme inhibito... growth factor a... hormone therapy protein tyrosin... somatostatin an... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma | NCT00003502 | Contiguous Stag... Noncontiguous S... Stage III Mantl... Stage IV Mantle... Recurrent Mantl... | antineoplaston ... antineoplaston ... alternative pro... biological ther... biologically ba... cancer preventi... complementary a... differentiation... | 18 Years - | National Cancer Institute (NCI) | |
| Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma | NCT00003505 | Primary Central... | antineoplaston ... antineoplaston ... alternative pro... biological ther... biologically ba... cancer preventi... complementary a... differentiation... | 18 Years - | National Cancer Institute (NCI) | |
| Celecoxib in Preventing Skin Cancer | NCT00025051 | Non-melanomatou... | celecoxib anti-cytokine t... antiangiogenesi... biological ther... cancer preventi... chemoprevention... growth factor a... | 20 Years - 60 Years | National Cancer Institute (NCI) | |
| Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease | NCT00462189 | Leukemia Hairy Cell Leuk... HCL | Immunotoxin the... CAT-8015 Immuno... Biological ther... | 18 Years - | Cambridge Antibody Technology | |
| Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission | NCT00101140 | Adult Acute Ery... Adult Acute Mon... Adult Acute Mye... | anti-thymocyte ... fludarabine pho... thiotepa biological ther... bone marrow abl... chemotherapy non-specific im... peripheral bloo... radiation thera... | 18 Years - 59 Years | Eastern Cooperative Oncology Group | |
| Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer | NCT00253526 | Adenocarcinoma ... Recurrent Pancr... Stage I Pancrea... Stage II Pancre... Stage III Pancr... | bevacizumab gemcitabine hyd... adjuvant therap... anti-cytokine t... antiangiogenesi... antibody therap... biological ther... chemotherapy conventional su... growth factor a... monoclonal anti... surgery | 18 Years - | National Cancer Institute (NCI) | |
| IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma | NCT00294476 | Cancer of Colon Malignant Melan... Urologic Cancer | IVIG Biological Ther... | 18 Years - | GammaCan | |
| Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease | NCT00462189 | Leukemia Hairy Cell Leuk... HCL | Immunotoxin the... CAT-8015 Immuno... Biological ther... | 18 Years - | Cambridge Antibody Technology | |
| Antineoplaston Therapy in Treating Patients With Colon Cancer | NCT00003486 | Stage IV Colon ... Recurrent Colon... Adenocarcinoma ... | antineoplaston ... antineoplaston ... alternative pro... biological ther... biologically ba... cancer preventi... complementary a... differentiation... | 18 Years - | National Cancer Institute (NCI) | |
| Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer | NCT00400803 | Carcinoma, Non-... | Gemcitabine, Ca... | 18 Years - | Masonic Cancer Center, University of Minnesota |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
